Xencor Inc (XNCR) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
Total Assets Chart for Xencor Inc
Xencor Inc (XNCR) total assets for FY2025 were USD 875.5M, a -8.0% change from FY2024. Xencor Inc's total assets grew from USD 22.4M in 2011 to USD 875.5M in 2025 (3813.0% over 14 years). Total assets compound annual growth rate: 5-year CAGR of 4.5%, 10-year CAGR of 15.5%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $1.70B
- Implied Share Price
- $22.85
- Enterprise Value
- $1.52B
- Revenue (TTM)
- $104.97M
- EBITDA
- -$205.90M
- Profit Margin
- -155.59%
- Trailing P/E
- —
- Forward P/E
- 68.03
- Price/Book (MRQ)
- 3.58
- Price/Sales (TTM)
- 16.18
- EV/EBITDA
- -17.27
- EV/Revenue
- 14.45
- Dividend Yield
- —
- Book Value
- $6.77
- Free Cash Flow (FY2025)
- -$138.27M
- Free Cash Flow Yield
- -8.14%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.